Alzheimer's: the numbers we cannot forget

David Cooney|19th July 2016

Normally in our blogs and articles at Blue Latitude Health we offer up snapshots of things we have learned from our experience working in a therapy area. I would love to be talking about our latest thinking around launching new therapies in Alzheimer’s disease (AD) but I can’t – no one can. This is because in the last 13 years, only one new drug has been approved for patients with AD. The most recently approved drug was in 2014, bringing the total number of agents approved across AD to 5.

In this article, I’m going to explore the success rate of trials in AD and the reasons for this incredulous situation, as well as look at the some of the glimmers of light at the end of the tunnel.

Among the worst attrition rates in the industry

99.6% of all trials in Alzheimer’s disease (AD) between 2002 and 2012 failed. This is one of the highest clinical trial failure rates in healthcare. During this period, 413 trials were performed using 95 compounds with 8 unique modes of action (MOAs). 35.1% of these studies were with disease modifying agents, 36.6% were symptomatic agents aimed at improving cognition, while 18% were disease modifying immunotherapies. Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose from:

 

These therapies have shown significant, but clinically marginal, benefits in relation to cognition, daily function, and behaviour. Patients on these therapies remain stable for approximately a year or more, with a slower subsequent rate of decline to untreated patients.

So what is the problem? Has there been sufficient investment from industry? Why haven’t we optimised the activity of proven active agents for better results? Why haven’t we identified more potent targets in the disease pathology with all the recent developments in genetics

Has pharma been investing in Alzheimer ’s disease?

They have - 78% of all trials in AD from 2002 to 2012 were funded by the pharmaceutical industry. If we consider that the mean duration of a phase 3 trial in AD is 90.9 weeks, with an average of 833 patients, and a 0.04% likelihood of success - the cost of AD trials and the amount of investment that has been made with little to no return is shocking. When you consider the success rate of a new oncology therapy is 19%, any company continuing to invest in this area deserves credit because the unmet need in AD is hard to fathom. The number of deaths in AD per year is on par with cancer, and the annual cost of care actually exceeds that of cancer - which is surprising considering there is 10x more research funding in cancer than AD.  This is an area in dire need of innovation, and with significant reward for whoever can make that breakthrough given the market valuation at $6.5billion

Download the full article from Blue Latitude Health

Genetic counsellors: the new healthcare influencers?

Natasha Cowan|28th August 2018

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

read more

The big question: are you faking your innovation?

Elisa del Galdo|23rd August 2018

Director and Head of Customer Experience Elisa del Galdo reveals the meaning of innovation and why creating a cutting-edge solution is much easier than you think.

read more

Mastering the precision medicine opportunity

David Cooney|16th August 2018

The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can plan for this change.

read more